Avandia Meeting Spurs New Scrutiny Of FDA Conflict-Of-Interest Screening
Executive Summary
Revelations about speaking and consulting agreements between two FDA advisory committee members, Avandia maker GlaxoSmithKline and Actos maker Takeda, suggest the agency may need to further refine its conflict-of-interest screening procedures to ensure a public perception that it is receiving independent advice from outside experts